Last reviewed · How we verify
6MPindividualized
6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation.
6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Autoimmune conditions requiring immunosuppression.
At a glance
| Generic name | 6MPindividualized |
|---|---|
| Also known as | PuriNethol, Puri-Nethol (6-mercaptopurine) |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Purine analog, immunosuppressant |
| Target | Purine metabolism pathway (HGPRT, TPMT) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
6MP is converted intracellularly to active metabolites that interfere with purine metabolism and DNA synthesis, leading to reduced proliferation of lymphocytes and other rapidly dividing cells. The drug is used in individualized dosing regimens, likely guided by thiopurine methyltransferase (TPMT) genotyping or metabolite monitoring to optimize efficacy while minimizing toxicity.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Autoimmune conditions requiring immunosuppression
Common side effects
- Myelosuppression (leukopenia, thrombocytopenia)
- Hepatotoxicity
- Nausea and vomiting
- Infection risk
- Pancreatitis
Key clinical trials
- ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6MPindividualized CI brief — competitive landscape report
- 6MPindividualized updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI